Targeting SUMOylation in cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• SUMOylation regulates critical cellular processes like gene transcription, DNA repair, cell cycle, and immunity.
• Aberrant SUMOylation pathway enzyme levels are associated with various cancers, correlating with disease progression and adverse patient outcomes.

Purpose of the Study:

• To review the multifaceted role of SUMOylation in tumorigenesis and cancer progression.
• To discuss SUMOylation's involvement in epithelial-mesenchymal transition (EMT), metastasis, therapeutic resistance, and antitumor immunity.
• To explore the clinical potential of small ubiquitin-like modifier (SUMO) inhibitors in cancer therapy.

Main Methods:

• Literature review of recent studies on SUMOylation in cancer.
• Analysis of SUMOylation's regulatory mechanisms in key cancer processes.
• Examination of clinical data and trials related to SUMOylation inhibitors.

Main Results:

• SUMOylation significantly influences EMT and metastasis by modulating key proteins like E-Cadherin and Snail.
• SUMOylation is implicated in resistance to chemotherapy and hormone therapy.
• SUMOylation regulates antitumor immune responses involving dendritic cells and T cells.
• The first-in-class SUMO E1 inhibitor, TAK-981, has advanced to clinical trials.

Conclusions:

• SUMOylation is a critical player in tumor EMT, metastasis, therapy resistance, and immune evasion.
• Targeting SUMOylation pathways represents a promising therapeutic strategy to enhance existing cancer treatments, including chemotherapy and immunotherapy.